Acute effects
Not the mechanism; carnitine works through slow tissue loading.
Protocol / Research Dosing Guide
L-Carnitine Dosage Guide: 500–2,000 mg Protocols and Route Math
An evidence-organized L-Carnitine reference explaining why oral absorption is limited, how the injectable 500 mg/mL solution differs, and which forms map to which research endpoints.
Last reviewed September 16, 202615 minute readResearch information only
Level 4 — Multiple controlled human studiesDietary supplement and research-grade injectableNot an approved weight-loss treatment
L-Carnitine Quick Start
Across the human literature L-carnitine doses cluster in a narrow band of 500 to 2,000 mg per day, with most well-known exercise and fatigue trials landing at 2 g daily. The unusual part of the dosing conversation is the route gap: supplemental oral L-carnitine has bioavailability near 15 percent, which is the entire reason injectable and intravenous forms exist and why a capsule label and a vial label do not mean the same thing in the bloodstream.
Why researchers care
Mitochondrial fatty-acid transport, exercise recovery, fatigue and metabolic research
Class
Amino-acid-derived compound, not a peptide
Route reported
Oral capsule or powder, and injectable 500 mg/mL solution
Cycle length
Daily use in trials; no fixed cycle established
Regulatory status
Available as a dietary supplement; injectable forms are research-grade or prescription depending on the product
Loading supplier information
L-Carnitine Dosing Protocol and Schedule
The supplied source reports 500–2,000 mg per day across human trials, 2 g/day in exercise-recovery and fatigue research, pooled weight-loss trials near 1.8–2 g/day, and a 500 mg/mL injectable concentration.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Common daily total | 500–2,000 mg per day across human trials | Clinical literature |
| Exercise recovery (LCLT) | 2 g per day | Volek 2002, PMID 11788381 |
| Fatigue and cognition (base form) | 2 g per day | Malaguarnera 2007, PMID 18065594 |
| Weight-loss trials (pooled) | About 1.8–2 g per day | Pooyandjoo 2016, PMID 27335245 |
| Injectable draw | 1.0 mL = 500 mg at 500 mg/mL | Calculation reference |
These figures are doses documented in published trials, reported rather than prescribed. Which form and total a study used depended on its endpoint.
L-Carnitine Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled vial or supplement container
Research planning item
Syringes sized for a 1 mL or larger draw when using an injectable solution
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration where the product label requires it
Research planning item
Written concentration label for any product prepared from powder
L-Carnitine Reconstitution Calculator
Vial-format concentration math
Concentration
500 mg/mL
Draw volume
1 mL
U-100 units
100
Mathematical draws
10
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take L-Carnitine: Morning or Night?
Time of day?
Trials used daily totals rather than a validated single time of day.
Split dosing?
Gram-scale oral totals are commonly divided because intestinal transporters saturate.
With food?
Oral absorption is limited regardless; higher single oral doses do not raise absorption proportionally.
Missed amount?
No validated replacement procedure; daily totals resume at the next scheduled time in trial protocols.
L-Carnitine Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Oral capsule or powder | Bioavailability near 15 percent; gram-scale totals used in trials | Surplus is largely excreted |
| Injectable solution | Typically 500 mg/mL; bypasses the gut absorption ceiling | Product labeling varies by vendor |
| Intravenous | Used clinically in carnitine-deficiency states | Clinician directed |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
L-Carnitine Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Oral bioavailability | About 15 percent of a supplemental dose | Published pharmacokinetics |
| Transporter saturation | Intestinal carnitine transporters saturate at supplement-scale doses | Published pharmacokinetics |
| Injectable route | Bypasses intestinal transport entirely | Reported rationale |
| Tissue loading | Muscle carnitine change is slow and is the reason trials run for weeks | Reported rationale |
L-Carnitine Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Oral | 500–2,000 mg | Daily | Clinical literature | Yes |
| Oral (LCLT) | 2 g | Daily | Exercise recovery trial | Yes |
| Oral (base form) | 2 g | Daily | Fatigue and cognition trial | Yes |
| Injectable | 500 mg | 1.0 mL at 500 mg/mL | Calculation reference | No |
| Injectable | 1,000 mg | 2.0 mL at 500 mg/mL | Calculation reference | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
L-Carnitine Reconstitution Guide
Concentration: 500 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 500 mg | 1 mL | 100 units |
| 1,000 mg | 2 mL | 200 units |
| 1,500 mg | 3 mL | 300 units |
- 1.Research-grade L-carnitine is usually sold pre-dissolved, so reconstitution arithmetic is often unnecessary.
- 2.Confirm the concentration printed on the vendor's label; 500 mg/mL is the standard research preparation.
- 3.A 10 mL vial at 500 mg/mL holds 5,000 mg, which is ten 500 mg draws or five 1,000 mg draws.
- 4.Where a product ships as powder, dissolve to a known concentration with bacteriostatic water before drawing.
- 5.Clean the stopper with an alcohol swab before each draw.
- 6.Record the concentration and the preparation or first-use date on the vial.
- 7.Do not assume a capsule milligram figure and a vial milligram figure deliver the same amount to the bloodstream.
- 8.Refrigerate where the product label requires it.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How L-Carnitine Works
Core role
L-carnitine runs the carnitine shuttle, ferrying long-chain fatty acids across the inner mitochondrial membrane so they can be burned for energy.
L-Carnitine Human Trials and FDA Status
Current status · verified September 16, 2026
Available as a dietary supplement; injectable forms are research-grade or prescription depending on the product
- Volek's 2002 crossover study (PMID 11788381) used 2 g per day of L-carnitine L-tartrate and reported attenuated markers of exercise-induced muscle disruption after a squat protocol.
- A 2021 randomized, double-blind, placebo-controlled trial (PMID 34684429) ran L-carnitine tartrate for five weeks and reported improved recovery and reduced post-exercise fatigue across both sexes in a 21–65 age range.
- Malaguarnera's 2007 work (PMID 18065594) used 2 g per day of the base form for fatigue and cognition endpoints.
- A pooled weight-loss analysis (PMID 27335245) covered trials near 1.8–2 g per day.
Who Should Avoid L-Carnitine?
This is an evidence-gap and precaution list, not an approved prescribing label.
Seizure disorders
Reported caution in carnitine literature
Hypothyroidism
Carnitine can interfere with thyroid hormone action at the cellular level
Kidney impairment or dialysis
Carnitine handling changes; clinician direction required
Pregnancy or breastfeeding
Use only under clinician direction
Warfarin therapy
Interaction has been reported and requires monitoring
L-Carnitine Side Effects, Risks and Safety
Fishy body odorReported
Important limitation: The most characteristic dose-related effect.
Gastrointestinal upsetReported
Important limitation: More common at gram-scale oral totals.
NauseaReported
Important limitation: Dose related.
Injection-site reactionReported
Important limitation: Applies to injectable preparations.
TMAO productionDocumented
Important limitation: Gut bacteria convert carnitine to TMAO; long-term cardiovascular relevance is debated.
Warfarin interactionReported
Important limitation: Requires clinical monitoring.
L-Carnitine Timeline and Monitoring
Trial durations
Recovery and fatigue trials commonly run several weeks.
Monitoring
Trials used endpoint-specific measures rather than a general monitoring schedule.
Stopping rules
Not defined outside trial protocols.
L-Carnitine Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Exercise recovery | Trial evidence with LCLT | Level 4 | 2 g per day |
| Fatigue and cognition | Trial evidence with base and ALCAR forms | Level 4 | 2 g per day |
| Weight loss | Small pooled effect | Level 4 | Modest and diet-dependent |
| Carnitine deficiency | Established clinical use | Level 5 | Clinician directed |
L-Carnitine Storage and Handling
Oral capsules or powder
Store per label, cool and dry.
Injectable solution
Follow the product label; many preparations require refrigeration after first use.
Freezing
Not required for a pre-dissolved solution; follow the label.
Appearance
Discard discolored or particle-containing solution.
L-Carnitine Troubleshooting
Capsule and vial milligrams seem equivalent
They are not. Oral bioavailability is near 15 percent, so the same milligram figure delivers very different amounts.
Fishy odor develops
A recognized dose-related effect; reported practice lowers the total.
Stomach upset at gram-scale totals
Dividing the daily total across the day is the common adjustment in trials.
Which form to research
Endpoint decides: LCLT for recovery, ALCAR for cognition, base or injectable for metabolic and deficiency contexts.
Taking warfarin
Seek clinical review before use; an interaction has been reported.
L-Carnitine Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Base L-carnitine | Metabolic and fatigue endpoints | Gram-scale oral totals | Also the injectable form |
| ALCAR | Brain-penetrant acetyl form | Cognition and mood research | Not interchangeable |
| LCLT | L-tartrate form | Most exercise-recovery trials | Not interchangeable |
| Propionyl-L-carnitine | Vascular research form | Different endpoint literature | Not interchangeable |
L-Carnitine Frequently Asked Questions
Is L-carnitine a peptide?
No. It is an amino-acid-derived compound the body also makes itself.
What is the common dose range?
500 to 2,000 mg per day across human trials.
Why do oral trials use grams?
Supplemental oral bioavailability is near 15 percent because intestinal transporters saturate.
What does the injectable solution contain?
Typically 500 mg/mL, so a 10 mL vial holds 5,000 mg.
How much is a 500 mg draw?
1.0 mL at 500 mg/mL.
Which form is used for recovery research?
L-carnitine L-tartrate, at 2 g per day in the best-known trials.
Which form crosses into the brain?
Acetyl-L-carnitine.
Does it cause weight loss?
Pooled trials report a small effect; it is not an approved weight-loss treatment.
What is the fishy odor about?
A recognized dose-related effect of carnitine metabolism.
Is there a warfarin interaction?
An interaction has been reported and requires clinical monitoring.
What is TMAO?
A compound gut bacteria produce from carnitine; its long-term cardiovascular relevance is debated.
Sources and Research
Coverage source
1. L-Carnitine dosing guide coverage source
Supplied coverage source for dose ranges, route comparison and injectable arithmetic.
Open direct sourceRandomized human trial
2. Volek 2002, L-carnitine L-tartrate and exercise-induced muscle disruption
Crossover study using 2 g per day of LCLT.
Open direct sourceRandomized human trial
3. Malaguarnera 2007, L-carnitine and fatigue in centenarians
Randomized trial using 2 g per day of the base form.
Open direct sourceMeta-analysis
4. Pooyandjoo 2016, L-carnitine and weight loss meta-analysis
Pooled analysis of trials near 1.8–2 g per day.
Open direct sourceRandomized human trial
5. L-carnitine tartrate recovery trial, 2021
Randomized, double-blind, placebo-controlled five-week recovery trial.
Open direct sourceMissing information flagged for review
- Standardized injectable dosing protocol outside clinical deficiency use: Not established
- Long-term TMAO risk resolution: Not established
- Validated cycle structure: Not established
- Direct head-to-head form comparisons for most endpoints: Not established